Spots Global Cancer Trial Database for ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Official Title: Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Study ID: NCT00325351
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Detailed Description: This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Tucson, Arizona, United States
, Little Rock, Arkansas, United States
, Bakersfield, California, United States
, La Jolla, California, United States
, San Diego, California, United States
, Savannah, Georgia, United States
, South Bend, Indiana, United States
, Baltimore, Maryland, United States
, Albuquerque, New Mexico, United States
, Winston-Salem, North Carolina, United States
, Cleveland, Ohio, United States
, Oklahoma City, Oklahoma, United States
, Knoxville, Tennessee, United States
, Roanoke, Virginia, United States
, Calgary, Alberta, Canada
, Toronto, Ontario, Canada
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
